GMP Requirements for Biotechnological Medicinal Products

Biotechnological medicines, or biologics, are produced using living systems such as cells or microorganisms. Unlike chemically synthesized drugs, they are highly complex, sensitive to process changes, and exhibit natural variability, making strict quality control essential.

In Europe, regulation is based on Directive 2001/83/EC and detailed in EudraLex Volume 4, including Part I (finished products), Part II (active substances), and Annex 2 (biological products). Sterile requirements are covered in Annex 1.

Globally, International Council for Harmonisation guidelines such as Q5A, Q5D, and Q6B address virus safety, cell banks, and product specifications.

Key GMP priorities include controlling biological variability, ensuring virus safety, and maintaining robust process control. Critical parameters like temperature and pH must be tightly monitored.

Extensive analytical testing ensures identity, purity, and potency, while risk-based contamination control, cleanroom strategies, and validated cleaning processes are essential for consistent product quality and patient safety.

22-03-2026